Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-445 Combination Therapy in Cystic Fibrosis (F/MF)
NCT03525444Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of elexacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Jun 2018; status: completed.
02
Drugs
elexacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03525444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03525444.